WEBHELP
20.12.2022 15:02:09 CET | Business Wire | Press release
Webhelp, a leading global customer experience BPO player, has announced that this year it has achieved its highest global growth since inception, with operations now spanning more than 60 countries and with close to 125,000 people employed globally. Webhelp also won more than 50 industry awards this year, was recognized as a leader in the Gartner Magic Quadrant for Customer Service BPO, and earned top ratings in Customer Experience globally by Analyst Everest Group.
Across the year, Webhelp expanded in 24 new locations and six new countries – Thailand, Bosnia Herzegovina, Ghana, Israel, North Macedonia, and China – with a further 18 new site openings in existing locations across the United States, Latin America, Asia Pacific, and Europe, Middle East and Africa. Webhelp also experienced very strong client growth in 2022, onboarding over 240 new logo clients across the world, and welcoming more than 25,000 game-changers to the company. In line with increased demand, Webhelp continued to bolster hybrid and remote working through its Webhelp Anywhere proposition to deliver ultimate flexibility and scalability to clients and meet evolving employee work preferences.
“Growth is a team sport, and every single one of our people has had a part to play in this extraordinary year for Webhelp. We pride ourselves on the stellar work our game-changers deliver on behalf of our clients and look forward to continuing this trend in 2023, investing further in tech and people, to continue to provide the best possible solutions to our clients and their customers,” said Olivier Duha, CEO and Co-Founder of Webhelp.
Webhelp successfully completed a number of notable acquisitions and strategic investments, including the acquisition of Grupo Services in LATAM, the leading Brazilian providers of digitally enabled Customer Experience. In EMEA, Webhelp also joined forces with Uitblinqers to strengthen its position in the Dutch market and made additional investments with Gobeyond Partners, with the creation of a Nudge practice – a strategic unit that leverages behavioral economics to help organizations drive the best possible outcomes, through influencing customer behaviors.
“The past few years have taught us that connection and humanity are more important than ever. I’m incredibly proud to be at the helm of a fast-growing company that is leading the way in tech-enabled, human-centric Customer Experience,” continues Olivier Duha.
Webhelp has also been focusing on strengthening its sustainability and environmental social governance (ESG) practices. 12% of its workforce have been hired via an award-winning impact sourcing program, which includes hiring disadvantaged youth, reintegration initiatives to help female prisoners get into work, and an ecosystem that supports migrant and refugee employability. This year, Webhelp also partnered with SGS, the leading certification company, on a long-term initiative to safeguard frontline health and well-being.
Webhelp’s growth strategy underpins its desire to serve as a strategic blue ocean partner, leveraging a combination of global reach and hyper local expertise to unlock new value for its clients. Webhelp’s solutions and services are designed to be relevant and valuable for both digital native clients and businesses seeking to transform CX and drive strategic value and differentiation from it.
In 2023, Webhelp will continue its strategic growth, expanding further in new and current key locations across the world, including APAC, EMEA, and the Americas, as well as investments in people, technology, and innovation.
###
About Webhelp
Webhelp designs, delivers, and optimizes unforgettable human experiences for today’s digital world – creating game-changing customer journeys. From sales to service, content moderation to credit management, Webhelp is an end-to-end partner across all B2C and B2B customer journeys. Its over 110,000 passionate employees across more than 60 countries thrive on making a difference for the world’s most exciting brands. Webhelp is currently owned by its management and Groupe Bruxelles Lambert (Euronext: GBLB), a leading global investment holding, as of November 2019. For more information on Webhelp, visit Webhelp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom